- This event has passed.
CMRP Seminar Series
August 28, 2019 @ 12:30 pm - 1:30 pm
Microbeam Radiotherapy: A Vision of the Future of Modern Radiotherapy
Elisabeth Schültke, PhD
Although the last two decades have seen amazing progress in the concepts of and hardware for radiotherapy, malignant tumours like glioblastoma multiform and lung cancer are still considered radio resistant. The introduction of microbeam radiotherapy (MRT) into clinical radiotherapy could change this.
MRT is characterized by very high dose rates (several hundred Gy per second) and a spatial fractionation in the micrometre range.
MRT has shown promising results with regard to both tumour destruction and functional normal tissue preservation in small animal models of malignant brain tumour.
Recently, first animal studies have been conducted to test normal tissue response in lung tissue.
Summarizing the state of the art of MRT options and requirements are discussed to bring MRT to clinical trials
Trained in both Neurosurgery and Radiation oncology, Elisabeth has worked as a project leader in preclinical microbeam radiotherapy (MRT) for more than 15 years. As a PhD in Anatomy and Cell Biology, she feels at home in both the basic science and the clinical research communities, which helps her to connect easily with researchers from both backgrounds and connect them with each other in order to further the development of MRT. In 2013, she was instrumental in founding the interdisciplinary and international network SYRA3, supported by the European Union with the aim to advance MRT towards clinical trials. Elisabeth loves swimming and hiking, reading, writing, teaching and making music with friends.